Strides Pharma Science Acquires Multiple Generic Brands from Sandoz, Strengthening its Africa Business

Strides Pharma Science Ltd. has signed definitive agreements with Sandoz for the acquisition and in-licensing of certain branded generic products across the Sub-Saharan Africa (SSA) region. The transaction covers four key markets—Western Sahara, Ghana, Nigeria, and Kenya—where Strides has an established operating presence. The integration of Strides’ existing operations with the Sandoz portfolio is expected to position Strides among the top five pharmaceutical companies in the SSA region by sales, and among the top two within its represented markets. The portfolio comprises multiple established brands across the anti-infective, cardiovascular, and dermatology segments. Several of these products individually record annual sales exceeding USD One Million, significantly bolstering the existing business meaningfully. The upfront consideration for the proposed transaction is USD 12 Million, payable at closing. The transaction also provides for royalty payments to Sandoz based on a percentage of net sales of Distribution Products.